PTC Therapeutics (PTCT) Q3 Revenues Beat

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.89), $0.49 worse than the analyst estimate of ($1.40). Revenue for the quarter came in at $138.7 million versus the consensus estimate of $126.44 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Credo Technology shares rise on analyst support and conference comments
• PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy